A Phase I Single-Center, Randomized, Double-Blind, Placebo-Controlled, Combined Single Ascending Dose, Multiple Ascending Dose, and Food Effect Study to Investigate the Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of K-755 in Healthy Adult Volunteers
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 121
- 试验地点
- 1
- 主要终点
- Part A, B, C, D and E: Number of subjects with clinically significant change in body weight
研究概览
简要总结
This is a Phase 1 study designed to explore the safety, tolerability and pharmacokinetics of K-755 following oral administration to healthy male and female volunteers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Other
- 盲法
- Double (Participant, Investigator)
盲法说明
Masking for Part A (SAD) , Part B (MAD), Part E (MAD) open for Part C (FE) and Part D (FE)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Able to comprehend and willing to sign an ICF and to abide by the study restrictions.
- •Males or females, of any race, between 18 and 45 years of age.
- •Body mass index (BMI) between 18.0 and 28.0 kg/m
- •Hematology, clinical chemistry, and urinalysis test results within the reference ranges or showing no clinically relevant deviations, as judged by the Investigator.
- •No clinically significant abnormalities on the basis of medical history, physical examination findings, and vital signs.
- •All females must have a negative serum pregnancy test.
- •Able and willing to comply with the protocol and study procedures.
排除标准
- •Female subject who are pregnant or breastfeeding.
- •Subject with presence of active or recurring clinically significant cardiovascular, pulmonary, renal, endocrine, hepatic, neurologic, psychiatric, immunologic, hematologic, gastrointestinal, or metabolic disease requiring medical treatment.
- •Subject with any surgical or medical condition that might significantly alter the absorption, distribution, metabolism, or excretion of K-
- •Subject with presence of an active malignancy or within the past 5 years a malignancy of any type, other than basal cell carcinoma of the skin.
- •Subject has a history of type 1 hypersensitivity to any medication and/or clinically relevant food allergies.
- •Subject has a history of drug addiction.
- •Subject has a positive screen for drugs of abuse, cotinine or alcohol.
- •Subject has a history of regular alcohol consumption within 6 months of the study.
- •Subject has smoked tobacco within 6 months prior to Check-in, or has used non-inhaled tobacco- or nicotine-containing products within 3 months prior to Check-in.
- •Subject has used prescription or over-the-counter medications, dietary/nutritional supplements (except paracetamol or vitamin supplements)
- •Subject has used steroid medications (oral, inhaled, parenteral, or topical) within 30 days or 5 half-lives (whichever is longer) before study drug administration.
- •Subject has participated in an investigational drug study within 30 days or 5 half-lives (whichever is longer) before study drug administration.
- •Subject has a positive screen for hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus types 1 and 2 antigens/antibodies.
- •Subject has had a clinically significant acute illness within 4 weeks or other illness within 5 days before the first study drug administration.
- •Subject or a family member of the subject is a member of the professional or ancillary personnel working at the investigative site involved in the study.
- •Not suitable for entry into the study in the opinion of the Investigator.
- •Receipt of blood products within 2 months prior to Check-in.
研究组 & 干预措施
K-755 Part A (SAD)
干预措施: K-755 Part A (SAD) (Drug)
Placebo Part A (SAD)
干预措施: Placebo Part A (SAD) (Drug)
K-755 Part B (MAD)
干预措施: K-755 Part B (MAD) (Drug)
Placebo Part B (MAD)
干预措施: Placebo Part B (MAD) (Drug)
K-755 Part C (FE)
干预措施: K-755 Part C (FE) (Drug)
K-755 Part D (FE)
干预措施: K-755 Part D (FE) (Drug)
K-755 Part E (MAD)
干预措施: K-755 Part E (MAD) (Drug)
Placebo Part E (MAD)
干预措施: Placebo Part E (MAD) (Drug)
结局指标
主要结局
Part A, B, C, D and E: Number of subjects with clinically significant change in body weight
时间窗: Up to 28 days after last administration
Change in body weight (kg) at baseline and post dose will be measured. Clinical significance will be determined by the investigator.
Part A, B, C, D and E: Incidence and severity of Adverse Events
时间窗: Up to 28 days after last administration
A treatment-emergent adverse events (TEAE) will be summarized by treatment and overall, and summarized for each treatment by severity and relationship to study drug. All TEAEs leading to withdrawal, or SAEs, will be summarized.
Part A, B, C, D and E: Number of subjects with clinical laboratory test abnormalities
时间窗: Up to 28 days after last administration
The clinical laboratory will include hematology (hematocrit, hemoglobin, mean cell hemoglobin, mean cell hemoglobin concentration, mean cell volume, platelet count, red blood cell count, white blood cell count), clinical chemistry (alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, blood urea nitrogen, calcium, chloride, cholesterol, creatinine, creatine phosphokinase, direct bilirubin, estimated glomerular filtration rate, gamma glutamyl transferase, glucose. inorganic phosphate, iron, lactate dehydrogenase, phosphorus, potassium, sodium, total bilirubin, total CO2, total protein, triglyceride, urea, uric acid), and urinalysis (bilirubin, blood, color and appearance, glucose, ketones, leukocyte esterase, nitrite, pH, protein, specific gravity, urobilinogen, microscopic examination, electrolytes). Abnormality will be determined by the investigator.
Part A, B, C, D and E: Number of subjects with vital signs abnormalities
时间窗: Up to 28 days after last administration
The vital sign will include blood pressure (mmHg), pulse rate (bpm), respiratory rate (breaths/min), and body temperature (degree Celsius). Abnormality will be determined by the investigator.
Part A, B, C, D and E: Number of subjects with abnormal findings in physical examinations
时间窗: Up to 28 days after last administration
The physical examination will typically include general appearance, head and neck, eyes, ear, nose and throat, lymph nodes, thyroid, cardiovascular, respiratory, abdomen, nervous, skin, musculoskeletal, peripheral vascular and extremities and be performed at Investigator's discretion based on reported symptoms. Abnormality will be determined by the investigator.
次要结局
- Part A: t1/2 of K-755(Up to 28 days after single administration)
- Part C: t1/2 of K-755(Up to 14 days after single administration)
- Part D: Cmax of K-755(Up to 14 days after single administration)
- Part E: t1/2 of K-755(Up to 14 days after single administration)
- Part B: Cmax of K-755(Up to 28 days after repeated administration)
- Part D: AUC0-tlast of K-755(Up to 14 days after single administration)
- Part A: Tmax of K-755(Up to 28 days after single administration)
- Part C: AUC0-inf of K-755(Up to 14 days after single administration)
- Part C: AUC0-tlast of K-755(Up to 14 days after single administration)
- Part C: Tmax of K-755(Up to 14 days after single administration)
- Part A: AUC0-tlast of K-755(Up to 28 days after single administration)
- Part A: AUC0-inf of K-755(Up to 28 days after single administration)
- Part A: Cmax of K-755(Up to 28 days after single administration)
- Part B: AUC0-τ of K-755(Up to 28 days after repeated administration)
- Part C: Cmax of K-755(Up to 14 days after single administration)
- Part E: Cmax of K-755(Up to 14 days after single administration)
- Part B: Tmax of K-755(Up to 28 days after repeated administration)
- Part B: t1/2 of K-755(Up to 28 days after repeated administration)
- Part D: AUC0-inf of K-755(Up to 14 days after single administration)
- Part D: Tmax of K-755(Up to 14 days after single administration)
- Part D: t1/2 of K-755(Up to 14 days after single administration)
- Part E: AUC0-τ of K-755(Up to 14 days after single administration)
- Part E: Tmax of K-755(Up to 14 days after single administration)